Celebration

BitDeer.com Celebrates One-Year Anniversary With Big Giveaway

Retrieved on: 
Thursday, December 12, 2019
Sharing, Social economy, Celebration

On its first anniversary, the company is launching promotions to give back to its community as part of the celebrations.

Key Points: 
  • On its first anniversary, the company is launching promotions to give back to its community as part of the celebrations.
  • The company is sharing its harvest to its community as they have always been at the forefront of providing excellent transparent computing power sharing.
  • BitDeer.com was the first to launch a real-time computing power sharing system that garnered major media attention including Cointelegraph and CCN.
  • For interested parties looking to partake in the anniversary celebration, please visit https://www.bitdeer.com for more information.

AdventHealth Nicholson Center Unveils 3D Printing Prototype Lab

Retrieved on: 
Wednesday, December 4, 2019
Celebration, Florida, Emerging technologies, Industrial design, Industrial processes, AdventHealth Nicholson Center, Seventh-day Adventist Church, Articles, Design, 3D printing, AdventHealth, Computer-aided design, Technology

Nicholson Centers in-house engineers use the latest technology in 3D Computer-Aided Design (CAD) modeling and 3D printing to develop, test and refine inventions to improve clinical outcomes.

Key Points: 
  • Nicholson Centers in-house engineers use the latest technology in 3D Computer-Aided Design (CAD) modeling and 3D printing to develop, test and refine inventions to improve clinical outcomes.
  • Our expert team can help bring an idea from napkin sketch to reality, and our 3D printing capabilities allow inventors to hold an actual version of their device in their hands for evaluation, said Jodi Fails, B.S., Biomedical Engineer and Prototype Lab lead at AdventHealth Nicholson Center.
  • However, with Nicholson Centers Prototype Lab, we have the unique ability to take inventions straight from the printer to the lab for immediate testing on high-quality tissue.
  • Beyond the technology and testing capabilities at Nicholson Center, our experts bring the pivotal industry knowledge that is so crucial to the early stages of product development, said Lilly Graziani, Director of Corporate Development at AdventHealth Nicholson Center.

KETTLER breaks ground in celebration with first development in Florida

Retrieved on: 
Thursday, November 21, 2019
Geography of Florida, Greater Orlando, The Walt Disney Company, Kettler, Celebration, Florida, Celebration, Florida, Humans

CELEBRATION, Fla., Nov. 21, 2019 /PRNewswire/ -- KETTLER, one of greater Washington, D.C.'s leading real estate development and property management companies, takes foothold in Central Florida with the groundbreaking of 18.44 acres of land purchased from The Celebration Company, marking its first development in the state.

Key Points: 
  • CELEBRATION, Fla., Nov. 21, 2019 /PRNewswire/ -- KETTLER, one of greater Washington, D.C.'s leading real estate development and property management companies, takes foothold in Central Florida with the groundbreaking of 18.44 acres of land purchased from The Celebration Company, marking its first development in the state.
  • KETTLER, known for its experience in master-planned communities, mixed-use and luxury multifamily developments, plans to construct a 379-unit, midrise apartment community Delamarre in the heart of Celebration.
  • Leadership from KETTLER and community partners gathered on Nov. 19 to celebrate this milestone development for Celebration and Osceola County.
  • In line with the company's growth strategy, KETTLER continues to evaluate acquisition and development opportunities in the Orlando submarket, the Tampa/St.

Construction Underway for Dave & Buster's at Celebration Pointe

Retrieved on: 
Wednesday, November 20, 2019
Video arcades, Dave & Buster's, Gainesville, Florida, Celebration, Geography of Florida, Florida

GAINESVILLE, Fla., Nov. 20, 2019 /PRNewswire/ --Celebration Pointe, North Central Florida's premier mixed-use development conveniently located along Interstate 75 in Gainesville, today announced that construction has started on Dave & Buster's newest Florida location.

Key Points: 
  • GAINESVILLE, Fla., Nov. 20, 2019 /PRNewswire/ --Celebration Pointe, North Central Florida's premier mixed-use development conveniently located along Interstate 75 in Gainesville, today announced that construction has started on Dave & Buster's newest Florida location.
  • "Dave & Buster's will make a great addition to Celebration Pointe, adding yet another dimension of entertainment to one of the more unique and vibrant developments in all of Florida," said Ralph Conti, Development Partner, Celebration Pointe.
  • "We have high expectations for this new Celebration Pointe location as part of our growth in the Southeast," said John Mulleady, Dave & Buster's Senior Vice President of Development.
  • Like Celebration Pointe, Dave & Buster's is a place where people go to enjoy and celebrate life.

KemPharm Reports Third Quarter 2019 Results

Retrieved on: 
Thursday, November 14, 2019
Economy of New York City, NASDAQ, Economy of the United States, Finance, Financial markets

ET

Key Points: 
  • ET
    CELEBRATION, Fla., Nov. 14, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today reported its corporate and financial results for the quarter ended September 30, 2019.
  • For Q3 2019, KemPharm reported revenue of $11.5 million, which included the $10 million upfront payment, development cost reimbursements and consultation fee revenue generated under the KP415/KP484 License Agreement.
  • KemPharm will host a conference call and live audio webcast with slide presentation today, Thursday, November 14, 2019, at 5:30 p.m.
  • ET, to discuss its corporate and financial results for the third quarter 2019.

KemPharm to Report Third Quarter 2019 Results

Retrieved on: 
Tuesday, November 12, 2019
Chemical compounds, Drugs, Organic compounds, Euphoriants, RTT, Morphinans, Hepatotoxins, Benzhydrocodone, Social media, Hydrocodone, LinkedIn, Paracetamol

ET, to discuss its corporate and financial results for the third quarter 2019.

Key Points: 
  • ET, to discuss its corporate and financial results for the third quarter 2019.
  • An archive of the webcast and presentation will remain available for 90 days beginning at approximately 6:30 p.m.
  • In addition, KemPharm has received FDA approval for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.
  • For more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com or connect with us on Twitter , LinkedIn , Facebook and YouTube .

KemPharm Reports APADAZ® Will be Available Nationally Beginning in November 2019

Retrieved on: 
Thursday, October 31, 2019
Opioids, Chemical compounds, Drugs, Morphinans, Euphoriants, RTT, Hepatotoxins, Ketones, Benzhydrocodone, Hydrocodone, Analgesic, Paracetamol

Specifically, KVK-Tech has informed KemPharm that APADAZ and its authorized generic (AG-APADAZ) will be available nationally beginning in November 2019.

Key Points: 
  • Specifically, KVK-Tech has informed KemPharm that APADAZ and its authorized generic (AG-APADAZ) will be available nationally beginning in November 2019.
  • In addition, KemPharm has received FDA approval for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.
  • APADAZ is differentiated from other prescription opioids as it is the first FDA-approved product to contain a prodrug of hydrocodone.
  • Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics: Avoid use with APADAZ because they may reduce analgesic effect of APADAZ or precipitate withdrawal symptoms.

KemPharm Presents Study Highlighting Patient-Friendly Dosing Properties of KP415 at the 66th Annual American Academy of Child & Adolescent Psychiatry Meeting

Retrieved on: 
Tuesday, October 22, 2019
Psychoactive drugs, Chemical compounds, Organic compounds, Euphoriants, RTT, Morphinans, Stimulants, Methylphenidate, Benzhydrocodone, Attention deficit hyperactivity disorder, Hydrocodone, Attention deficit

KP415 is KemPharms prodrug product candidate of d-methylphenidate (d-MPH) being developed for the treatment of attention deficit hyperactivity disorder (ADHD).

Key Points: 
  • KP415 is KemPharms prodrug product candidate of d-methylphenidate (d-MPH) being developed for the treatment of attention deficit hyperactivity disorder (ADHD).
  • On September 3, 2019, KemPharm entered into a license and collaboration agreement with an affiliate of Gurnet Point Capital (GPC) for the commercial rights to KP415 and related development products.
  • In addition, KemPharm has received FDA approval for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.
  • For more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com or connect with us on Twitter , LinkedIn , Facebook and YouTube .

KemPharm to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Diseases

Retrieved on: 
Tuesday, September 17, 2019
Psychoactive drugs, Drugs, Amphetamine, Euphoriants, Methylphenidate, Childhood psychiatric disorders, Stimulant, Attention deficit hyperactivity disorder, Benzhydrocodone, Attention deficit

The Oppenheimer Fall Summit brings together the management teams from a select group of companies focused on specialty pharmaceuticals and orphan and rare diseases with investors to discuss therapeutic programs in development and recent corporate updates.

Key Points: 
  • The Oppenheimer Fall Summit brings together the management teams from a select group of companies focused on specialty pharmaceuticals and orphan and rare diseases with investors to discuss therapeutic programs in development and recent corporate updates.
  • KemPharms prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, and stimulant use disorder.
  • In addition, KemPharm has received FDA approval for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.
  • For more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com or connect with us on Twitter , LinkedIn , Facebook and YouTube .